TrivarX Limited (AU:TRI)
ASX:TRI
Want to see AU:TRI full AI Analyst Report?
TRI Stock Chart & Stats
AU$0.02
<AU$0.01(6.67%)
At close: 4:00 PM EST
AU$0.02
<AU$0.01(6.67%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.04
Previous CloseN/A
Volume87.40K
Average Volume (3M)1.22M
Market Cap
AU$34.61M
Enterprise ValueAU$33.53M
Total Cash (Recent Filing)AU$1.25M
Total Debt (Recent Filing)AU$169.03K
Price to Earnings (P/E)―
Beta2.70
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding1,153,693,500
10 Day Avg. Volume1,871,965
30 Day Avg. Volume1,217,195
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-54.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and a growing equity base provide a meaningful solvency cushion for an early-stage healthcare information business. That reduces short-term distress risk, supports continued product development or trials, and gives management time to pursue revenue or partnerships without immediate insolvency pressure.
Improving Cash Burn TrendMaterial reduction in free cash flow outflow indicates tighter cost control or lower cash intensity. If sustained this trend lengthens runway, reduces near-term financing needs and increases the chance management can reach commercial milestones or secure non-dilutive partnerships before major recapitalization.
Lean Operating StructureA very small headcount implies lower fixed overhead and operational flexibility. For a development-stage medical information firm, a lean cost base helps preserve cash, allows focused allocation to critical R&D or regulatory tasks, and makes incremental scaling less capital intensive.
Bears Say
Sustained Net LossesRepeated net losses erode retained capital and produce negative returns on equity (around -7.5%), limiting internal funding for growth. Persistent unprofitability increases reliance on external finance, raises dilution or interest burdens, and is a structural constraint until revenue or margins improve.
No Reported RevenueZero reported revenue removes visibility on product-market fit and unit economics. Without demonstrated sales, scaling, margin improvement and sustained profitability depend on successful commercialization or partnerships, making execution risk and financing dependency structural challenges.
Negative Operating Cash FlowNegative operating and free cash flow show the business is not self-sustaining; even with improvement, ongoing cash outflows necessitate external funding or equity raises. This limits strategic optionality, can delay commercialization investments, and increases medium-term financing risk.
TrivarX Limited News
TRI FAQ
What was TrivarX Limited’s price range in the past 12 months?
TrivarX Limited lowest share price was <AU$0.01 and its highest was AU$0.04 in the past 12 months.
What is TrivarX Limited’s market cap?
TrivarX Limited’s market cap is AU$34.61M.
When is TrivarX Limited’s upcoming earnings report date?
TrivarX Limited’s upcoming earnings report date is Aug 27, 2026 which is in 109 days.
How were TrivarX Limited’s earnings last quarter?
TrivarX Limited released its earnings results on Feb 24, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is TrivarX Limited overvalued?
According to Wall Street analysts TrivarX Limited’s price is currently Overvalued.
Does TrivarX Limited pay dividends?
TrivarX Limited does not currently pay dividends.
What is TrivarX Limited’s EPS estimate?
TrivarX Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TrivarX Limited have?
TrivarX Limited has 1,153,693,500 shares outstanding.
What happened to TrivarX Limited’s price movement after its last earnings report?
TrivarX Limited reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.696%.
Which hedge fund is a major shareholder of TrivarX Limited?
Currently, no hedge funds are holding shares in AU:TRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TrivarX Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-7.84%
Trailing 12-Months
Asset Growth
112.47%
Trailing 12-Months
Company Description
TrivarX Limited
TrivarX Limited, a health technology company, engages in the development of AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. The company was formerly known as Medibio Limited and changed its name to TrivarX Limited in October 2023. TrivarX Limited was incorporated in 1987 and is based in Mount Lawley, Australia.
Technical Analysis
Resonance Health Ltd
―
Opyl Ltd.
―
MedAdvisor Limited
―
InteliCare Holdings Limited
―
PainChek Ltd
―
Options Prices
Currently, No data available
---